From The Banner · Meredith Cohn · · 1m 30s
mFlusiva mRNA flu vaccine ready for 50+
Moderna's new mRNA flu shot mFlusiva is ready for people 50 and older, offering faster production and better flu protection.
In brief
Moderna's new mRNA flu shot mFlusiva is ready for people 50 and older, offering faster production and better flu protection. Moderna's mRNA flu vaccine mFlusiva is approved for adults 50 and older, potentially providing better flu protection with quicker production than traditional vaccines. Originally reported by The…
New mRNA flu vaccine ready
Moderna's mFlusiva vaccine is ready for adults 50 and older, using the same mRNA platform as the COVID-19 vaccine.
“mFlusiva (pronounced em-floo-SEE-vah)”
Faster production process
mRNA vaccines don't require growing viruses in eggs, allowing quicker development and better flu strain matching.
“With mRNA vaccines, we can start closer to the start of the season, and the benefit is we may get a much better match”
Stronger immune response
Studies show mRNA vaccines induce a stronger immune response, potentially better protection against real-world flu virus.
“The real test will come this season, now that the vaccine is available”
Flu season timing
Public health officials urge Maryland residents to get vaccinated by October 31 to protect against flu season.
“before the end of October”
Who gets mFlusiva
mFlusiva was tested on adults 50 and older, including some 65 and up, with studies ongoing for younger adults and children.
“including some 65 and up”
Cost and insurance
mFlusiva could cost $150 to $180, with insurance coverage uncertain as insurers may not cover it.
“$150 to $180”
Benefits for healthy adults
Flu shots reduce hospitalizations, missed work, and lower risks of dementia and heart attacks.
“lower risk of dementia and heart attacks”
Safety concerns
mRNA vaccines have been used safely for millions during the pandemic, with no evidence of DNA alteration.
“it’s impossible for mRNA vaccines to alter DNA”
Future of mRNA vaccines
Durbin warns that stopping mRNA vaccine development for cancer could leave the U.S. behind globally.
“If the U.S. doesn’t continue with development of mRNA vaccines for cancer and other uses, the rest of the world will and we will be left behind”
At a glance
Moderna's mRNA flu vaccine mFlusiva is approved for adults 50 and older, potentially providing better flu protection with quicker production than traditional vaccines.
